Why is Jiangsu Kanion Pharmaceutical Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -1.96% and Operating profit at -16.74% over the last 5 years
2
With a fall in PBT of -13.33%, the company declared Very Negative results in Sep 25
- The company has declared negative results for the last 2 consecutive quarters
- INTEREST(9M) At CNY 9.06 MM has Grown at 30.23%
- OPERATING CASH FLOW(Y) Lowest at CNY 456.65 MM
- NET PROFIT(HY) At CNY 116.23 MM has Grown at -38.75%
3
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -1.35% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods
How much should you hold?
- Overall Portfolio exposure to Jiangsu Kanion Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Jiangsu Kanion Pharmaceutical Co., Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Jiangsu Kanion Pharmaceutical Co., Ltd.
-100.0%
-0.57
34.33%
China Shanghai Composite
20.18%
1.58
14.20%
Quality key factors
Factor
Value
Sales Growth (5y)
1.31%
EBIT Growth (5y)
-3.48%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
0.76
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.05%
ROE (avg)
8.24%
Valuation Key Factors 
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
1.41
EV to EBIT
20.94
EV to EBITDA
12.77
EV to Capital Employed
1.71
EV to Sales
1.51
PEG Ratio
1.85
Dividend Yield
NA
ROCE (Latest)
8.16%
ROE (Latest)
6.16%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Movement
4What is working for the Company
NET PROFIT(HY)
At CNY 183.57 MM has Grown at 55.39%
RAW MATERIAL COST(Y)
Fallen by -5.13% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 4.7 times
-5What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.99 times
OPERATING PROFIT(Q)
Lowest at CNY 87.21 MM
DEBT-EQUITY RATIO
(HY)
Highest at -41.55 %
Here's what is working for Jiangsu Kanion Pharmaceutical Co., Ltd.
Net Profit
At CNY 183.57 MM has Grown at 55.39%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
Debtors Turnover Ratio
Highest at 4.7 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -5.13% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Jiangsu Kanion Pharmaceutical Co., Ltd.
Operating Profit
Lowest at CNY 87.21 MM and Fallen
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite negative
Operating Profit (CNY MM)
Inventory Turnover Ratio
Lowest at 1.99 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debt-Equity Ratio
Highest at -41.55 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio






